SAM Holdings forms strategic review committee amidst continuing net loss

Returns from its proton beam therapy have been slower than expected.

The Singapore Institute of Advanced Medicine Holdings (SAM) has formed a strategic review committee (SRC) in its bid to address the company’s continuous net loss.

The ramp-up in SAM’s business on the proton beam therapy has been slower than expected due to delays in being included on the panels of healthcare providers of insurance companies, low patient flow, and competition.

The lower revenue with higher operating expenses has resulted in the group continuing to record net losses, negative working capital, and negative cash flow from operations.

The SRC, comprising of non-executive directors of the company, will assist the executive management team on various ongoing and new initiatives focused on improving proton beam therapy utilisation and photon radiation therapy facilities.